Baidu
map

Pediatrics:儿童结核病患者:传统疗法vs短期方案

2018-03-20 吴星 环球医学

2018年2月,发表在《Pediatrics》上的一项回顾性队列研究,在结核病(TB)感染的儿童中,对传统疗法和短期方案进行了比较,从而对短期方案治疗的安全性进行了评估。

2018年2月,发表在《Pediatrics》上的一项回顾性队列研究,在结核病(TB)感染儿童中,对传统疗法和短期方案进行了比较,从而对短期方案治疗的安全性进行了评估。

背景:报告显示,TB感染的传统疗法(每天使用异烟肼,为期9个月[9H])安全,但完成率<50%。短期方案(每周1次使用异烟肼和利福喷丁,为期3个月[3HP]或每天使用利福喷丁,为期4个月[4R])与成人依从性的改善相关。

方法:这是一项针对低收入国家儿童TB诊所中年龄在0至18岁儿童的回顾性队列研究(2014年~2017年)。研究者比较了使用3HP、4R以及9H儿童的完成率以及不良事件(AEs)的发生率;后2种方案可允许通过家庭(称作自我管理疗法[SAT])或直接观察的预防性治疗(DOPT)来实施;通常在DOPT的情况下给予3HP。

结果:在667例开始TB感染治疗的儿童中:283例(42.4%)使用3HP,252例(37.8%)使用9H,132例(19.8%)使用4R。通过SAT 使用9H的儿童中仅有52%的儿童完成了治疗。使用3HP的儿童比使用9H(SAT)的儿童完成治疗的可能性更大(比值比[OR] 27.4,95% 置信区间[CI]:11.8~63.7)。多变量分析发现,在DOPT的情况下使用药物(OR:5.72,95% CI:3.47~9.43)、年龄增加(OR:1.09,95% CI:1.02~1.17),以及不发生AE(OR:1.70,95% CI:0.26~0.60)与完成治疗相关。在9H组中,AEs更常见(OR:2.51,95% CI:1.48~4.32)。2例(0.9%)使用9H的儿童出现肝脏毒性;使用3HP或4R的儿童没有出现肝脏毒性。

结论:与9H方案相比,短期方案增加完成率、降低AEs发生率。

原始出处:

Cruz AT and Starke JR. Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens. Pediatrics. 2018 Feb;141(2). pii: e20172838. doi: 10.1542/peds.2017-2838.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638497, encodeId=0fbe163849edf, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 27 14:15:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727168, encodeId=7ca11e271687d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 17 11:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746217, encodeId=bba41e4621712, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Jan 04 19:15:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958534, encodeId=88fd195853432, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 11 04:15:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254149, encodeId=9d74125414950, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Mar 22 06:15:00 CST 2018, time=2018-03-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1638497, encodeId=0fbe163849edf, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 27 14:15:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727168, encodeId=7ca11e271687d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 17 11:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746217, encodeId=bba41e4621712, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Jan 04 19:15:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958534, encodeId=88fd195853432, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 11 04:15:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254149, encodeId=9d74125414950, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Mar 22 06:15:00 CST 2018, time=2018-03-22, status=1, ipAttribution=)]
    2018-08-17 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1638497, encodeId=0fbe163849edf, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 27 14:15:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727168, encodeId=7ca11e271687d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 17 11:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746217, encodeId=bba41e4621712, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Jan 04 19:15:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958534, encodeId=88fd195853432, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 11 04:15:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254149, encodeId=9d74125414950, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Mar 22 06:15:00 CST 2018, time=2018-03-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1638497, encodeId=0fbe163849edf, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 27 14:15:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727168, encodeId=7ca11e271687d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 17 11:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746217, encodeId=bba41e4621712, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Jan 04 19:15:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958534, encodeId=88fd195853432, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 11 04:15:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254149, encodeId=9d74125414950, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Mar 22 06:15:00 CST 2018, time=2018-03-22, status=1, ipAttribution=)]
    2018-10-11 hbwxf
  5. [GetPortalCommentsPageByObjectIdResponse(id=1638497, encodeId=0fbe163849edf, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 27 14:15:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727168, encodeId=7ca11e271687d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 17 11:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746217, encodeId=bba41e4621712, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Jan 04 19:15:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958534, encodeId=88fd195853432, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 11 04:15:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254149, encodeId=9d74125414950, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Mar 22 06:15:00 CST 2018, time=2018-03-22, status=1, ipAttribution=)]

相关资讯

Clin Infect Dis:神药二甲双胍还能辅助结核病治疗?

二甲双胍历经整整60多载的风雨洗礼,久经考验成为了当今世界范围内2型糖尿病(DM)降糖治疗的基石。不仅如此,其糖尿病以外的应用价值持续不断的被发掘。时至今日,其仍在不断给我们惊喜,是当之无愧的神药。

结核病重症加强治疗病房建设与管理专家共识(2018)

结核病是由结核分枝杆菌(mycobacterium tuberculosis,MTB)引起的经呼吸道传播的传染病,在全球广泛流行,是世界性的重大公共卫生问题之一。世界卫生组织2016年报道,2015年全球新发结核病1 040万例,140万人死于该病,防治形势依然严峻。近年来,虽然结核病诊疗技术发展迅速,但仍有1%~3%的患者进展为重症结核病,其中呼吸衰竭和多器官功能障碍综合征是重症结核病患者收入结

结核病预防有中国医生的贡献

肺痨——一个让人类恐惧了多个世纪的疾病,每年仍然夺去数以百万计的生命。看到近日湖南一中学结核病集中发病的新闻,不由得想起了曾在美国休斯敦遇到的许汉光医生。

重庆对高二学生每年筛查结核病

近日,重庆市教委、卫生计生委联合印发《重庆市学校结核病防控工作规范》,明确各级各类学校按有关规定将结核病检查项目作为新生入学体检和教职员工常规体检的必查项目。并规定,各中学(包括普通高中和普通职业高中)应每年组织高二年级学生进行结核病筛查。

Eur Respir J:全球青少年结核病发病率估计!

由此可见,年轻人患肺结核病的负担很重。这个年龄段的年龄特异性疾病负担估计常常存在结核病数据中年龄分类不完整,突出了继续加强监视系统建设的重要性。

2017 CHEST指南:结核病和其他慢性感染引起的咳嗽

咳嗽是肺结核和其他慢性呼吸道感染的常见症状,本文是对2006年ACCP指南关于结核病和其他慢性感染引起的咳嗽章节的更新,主要目的是确定肺结核咳嗽患者检测的最佳时间和诊断策略。全文共提出了8个关键问题,并针对这些关键问题提出建议。

Baidu
map
Baidu
map
Baidu
map